Kodiak Sciences
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 111
- Market Cap
- $138.9M
- Introduction
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was f...
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 675
- Registration Number
- NCT06556368
- Locations
- ๐บ๐ธ
California Retina Consultants, Oxnard, California, United States
๐บ๐ธRetina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
๐บ๐ธNational Ophthalmic Research Institute, Fort Myers, Florida, United States
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
- Conditions
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 250
- Registration Number
- NCT06270836
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธAsheville Eye Associates, Asheville, North Carolina, United States
๐บ๐ธNorth Carolina Retina Associates (Cary), Cary, North Carolina, United States
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
- Conditions
- Interventions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 253
- Registration Number
- NCT05066230
- Locations
- ๐บ๐ธ
Charleston Neurosciences Institute, Beaufort, South Carolina, United States
๐บ๐ธRetina Specialists of Idaho, Boise, Idaho, United States
๐ช๐ธHospital Universitario Miguel Servet, Zaragoza, Spain
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 557
- Registration Number
- NCT04964089
- Locations
- ๐บ๐ธ
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
๐บ๐ธRetina Consultants of Texas, Houston, Texas, United States
๐บ๐ธMedical Center Ophthalmology Associates, San Antonio, Texas, United States
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 460
- Registration Number
- NCT04611152
- Locations
- ๐บ๐ธ
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
๐บ๐ธMidAtlantic Retina, Philadelphia, Pennsylvania, United States
๐บ๐ธOphthalmic Consultants of Boston, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 459
- Registration Number
- NCT04603937
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, United States
๐ซ๐ทCHRU Dijon Complexe Du Bocage, Dijon, Cรดte-d'Or, France
๐บ๐ธRetina Specialists of Idaho, Boise, Idaho, United States
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 568
- Registration Number
- NCT04592419
- Locations
- ๐บ๐ธ
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
๐บ๐ธVitreo Retinal Consultants and Surgeons, Wichita, Kansas, United States
๐บ๐ธTennessee Retina PC, Nashville, Tennessee, United States
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 559
- Registration Number
- NCT04049266
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, United States
๐บ๐ธMedical Center Ophthalmology Associates, San Antonio, Texas, United States
๐บ๐ธVitreoretinal Surgery PA, Edina, Minnesota, United States
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
- Conditions
- Interventions
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 121
- Registration Number
- NCT03790852
- Locations
- ๐บ๐ธ
Retinal Research Institute, LLC, Phoenix, Arizona, United States
๐บ๐ธByers Eye Institute at Stanford, Palo Alto, California, United States
๐บ๐ธRetina Vitreous Associates Medical Group, Beverly Hills, California, United States